Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.41 |
| ▸ | KIT | P10721 | 4/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30863956 | 0.98 | HCAR2 (0.44) | HCAR2DYRK1ACSNK2A2KDRCSNK2B | |
| SCHEMBL15555717 | 0.80 | HCAR2 (0.37) | HCAR2CSNK2A2KDRCSNK2BCSNK2A1 | |
| SCHEMBL14190551 | 0.80 | HCAR2 (0.44) | HCAR2CSNK2A2KDRCSNK2BCSNK2A1 | |
| SCHEMBL4631308 | 0.79 | HCAR2 (0.63) | HCAR2DYRK1ADAO | |
| SCHEMBL24093956 | 0.78 | HCAR2 (0.42) | HCAR2CSNK2A2KDRCSNK2BCSNK2A1 | |
| SCHEMBL30300433 | 0.78 | HCAR2 (0.68) | HCAR2CSNK2A2KDRCSNK2BCSNK2A1 | |
| SCHEMBL31162505 | 0.77 | HCAR2 (0.50) | HCAR2DYRK1AKITPDE4DDAO | |
| SCHEMBL8723377 | 0.77 | DYRK1A (0.42) | HCAR2DYRK1ACSNK2A2KDRCSNK2B | |
| SCHEMBL28229219 | 0.77 | HCAR2 (0.50) | HCAR2CSNK2A2KDRCSNK2BCSNK2A1 | |
| SCHEMBL15601779 | 0.75 | PRKAB2 (0.38) | HCAR2CSNK2A2KDRCSNK2BCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024121779-A1 | PAPAIN-LIKE PROTEASE (PLPRO) INHIBITORS | PFIZER INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| CN-111269221-B | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2023-09-26 | — | — | CN | disclosed |
| EP-3083583-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF | SAGIMET BIOSCIENCES INC (US) | 2020-11-18 | — | — | EP | disclosed |
| US-10717711-B2 | Amino quinazolines as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-21 | — | — | US | disclosed |
| EP-3601259-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | H. Hoffnabb-La Roche Ag (CH) | 2020-02-05 | — | — | EP | disclosed |
| US-20190194145-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-06-27 | — | — | US | disclosed |
| CN-105308036-B | The Compounds and methods for and its indication adjusted for kinases | 普莱希科公司 | 2019-06-21 | — | — | CN | disclosed |
| US-10226449-B2 | Heterocyclic modulators of lipid synthesis and combinations thereof | 3-V BIOSCIENCES, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| WO-2018183964-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
| US-20180258056-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-09-13 | — | — | US | disclosed |
| EP-2603218-B1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-03-02 | — | — | EP | disclosed |
| US-20150290200-A1 | INTRACELLULAR KINASE INHIBITORS | PHARMACYCLICS INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20140256949-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-09-11 | — | — | US | disclosed |
| US-20140206688-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-24 | — | — | US | disclosed |
| EP-2744501-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2014-06-25 | — | — | EP | disclosed |
| US-20140080833-A1 | INTRACELLULAR KINASE INHIBITORS | MANNKIND CORPORATION (US) | 2014-03-20 | — | — | US | disclosed |
| EP-2603218-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-06-19 | — | — | EP | disclosed |
| WO-2013025958-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-02-21 | — | — | WO | disclosed |
| WO-2012021580-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | WO | disclosed |
| US-20120041024-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041024-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | ABL1, MAP3K20, MAP3K19 | HCAR2 2060/4885DYRK1A 187/4885CSNK2A2 222/4885 |
| US-20180258056-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | ABL1, MAP3K3, MAP4K2 | HCAR2 3011/4885DYRK1A 395/4885CSNK2A2 103/4885 |
| US-20190194145-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | ABL1, MAP3K3, MAP4K2 | HCAR2 3011/4885DYRK1A 395/4885CSNK2A2 103/4885 |
| US-10226449-B2 | Heterocyclic modulators of lipid synthesis and combinations thereof | FASN, FADS1, COASY | HCAR2 363/4885DYRK1A 3689/4885CSNK2A2 2446/4885 |
| US-20150290200-A1 | INTRACELLULAR KINASE INHIBITORS | PI4KB, BTK, LTK | HCAR2 3636/4885DYRK1A 640/4885CSNK2A2 575/4885 |
| US-20140256949-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | ABL1, MAP3K20, MAP3K19 | HCAR2 2060/4885DYRK1A 187/4885CSNK2A2 222/4885 |
| US-10717711-B2 | Amino quinazolines as kinase inhibitors | ABL1, MAP3K3, MAP4K2 | HCAR2 3011/4885DYRK1A 395/4885CSNK2A2 103/4885 |
| US-20140206688-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | ABL1, MAP3K3, MAP4K2 | HCAR2 2832/4885DYRK1A 409/4885CSNK2A2 93/4885 |
| US-20140080833-A1 | INTRACELLULAR KINASE INHIBITORS | PI4KB, BTK, LTK | HCAR2 3636/4885DYRK1A 640/4885CSNK2A2 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.